PASADENA 1-year open-label extension
Objective: To describe the results of PASADENA 1-year open-label extension (OLE). Background: Prasinezumab is a humanized monoclonal antibody that binds aggregated alpha-synuclein with the potential…Assessing the optimal pallidal target in deep brain stimulation for Parkinson’s disease: A single-center retrospective review
Objective: To characterize globus pallidus internus (GPi) deep brain stimulation (DBS) active contact location at one-year post-op for Parkinson’s disease (PD) patients at our center.…Effectiveness of use of Pictographs on Levodopa packaging to ensure awareness of Levodopa/Carbidopa spacing with meals in patients of Idiopathic Parkinson’s disease.
Objective: Food interferes with gastrointestinal absorption of levodopa which requires spacing with meals. This study aimed to evaluate the effect pictographs on Levodopa packaging Fig 1 on increasing patient…Continuous subcutaneous foslevodopa/foscarbidopa: final results from a phase 3, open-label study
Objective: Evaluate safety and efficacy of foslevodopa/foscarbidopa (LDP/CDP) for patients with Parkinson’s disease (PD) in a 52-week, phase 3 study. Background: As PD progresses, patients…Risk of hallucinations and amantadine treatment in levodopa-induced dyskinesia patients with Parkinson’s disease: a meta-analysis of randomized controlled trials
Objective: The present meta-analysis aims to find out association between risk of hallucinations and amantadine treatment in levodopa-induced dyskinesia (LID) patients with Parkinson’s disease (PD).…Epidemiology of late-onset Parkinson’s disease in least-developed to Upper Middle-Income Countries: A Systematic Review and Meta-analysis
Objective: To conduct a meta-analysis of the epidemiological studies of Parkinson's disease (PD) performed in populations from least-developed to upper-middle-income countries. Background: While several epidemiology…Safety and pharmacokinetics of anti-inflammatory NE3107 treatment in carbidopa/levodopa-treated patients with Parkinson’s disease: A phase 2a, double-blind, placebo-controlled study
Objective: To assess the safety, tolerability, and pharmacokinetics (PK) of NE3107 in carbidopa/levodopa (C/L)-treated patients with Parkinson’s disease (PD) Background: Disease-modifying therapies that augment the…Serum levels of IL-1β and interleukin 6 in Parkinson’s disease
Objective: We aim to assess IL-1 β and IL-6 serum levels in patients with PD and in controls and to explore their associations with clinical…Linking volume of tissue activated to neural oscillations in deep brain stimulation
Objective: Exploring the effect of deep brain stimulation (DBS) settings on neural oscillations in Parkinson’s disease (PD) patients with subthalamic nucleus (STN) DBS and their…At-home adaptive deep brain stimulation improves motor fluctuations and quality of life in patients with Parkinson’s disease: a single-blind randomized study
Objective: We evaluated the effect of at-home adaptive deep brain stimulation (aDBS) based on personalized neural biomarkers on motor symptoms and quality of life (QoL)…
- « Previous Page
- 1
- …
- 374
- 375
- 376
- 377
- 378
- …
- 553
- Next Page »